PMID- 37702180
OWN - NLM
STAT- MEDLINE
DCOM- 20240222
LR  - 20240222
IS  - 2212-3873 (Electronic)
IS  - 1871-5303 (Linking)
VI  - 24
IP  - 6
DP  - 2024
TI  - Interleukin-38 and Insulin Resistance.
PG  - 611-616
LID - 10.2174/1871530323666230911114150 [doi]
AB  - Insulin resistance, i.e., decreased biological response to insulin, is a risk 
      factor for many diseases, such as obesity, type 2 diabetes (T2DM), cardiovascular 
      disease, polycystic ovary syndrome, some forms of cancer and neurodegenerative 
      diseases. One of its main causes is chronic low-grade inflammation, mediated by 
      the proinflammatory pathways, such as the c-Jun N-terminal kinase (JNK) pathway 
      and the nuclear factor kappa B (NFkappaB) pathway. Interleukin (IL)-38 (IL-38) is a 
      newly discovered cytokine that belongs to the IL-1 family. There are three 
      hypothetical pathways through which IL-38 may bind to the specific receptors and 
      inhibit their proinflammatory activity. Those pathways are associated with IL-36 
      receptor (IL-36R), IL-1 receptor accessory protein-like 1 (IL1RAPL1) and IL-1 
      receptor 1 (IL1R1). There are studies linking IL-38 to improve insulin 
      sensitivity through the difference in serum IL-38 in patients with insulin 
      resistance or the correlation of IL-38 concentrations with insulin resistance 
      indexes. However, many questions still remain regarding the biological activity 
      of IL-38 itself and its role in the pathogenesis of insulin resistance. The goal 
      of this study is to showcase IL-38, its biological activity, hypothesized 
      signaling pathways, connection with insulin resistance and future perspectives of 
      research on IL-38. We present that IL-38 associated signaling can be a potential 
      target for the treatment of insulin resistance and associated diseases.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Klejbuk, Kamil
AU  - Klejbuk K
AUID- ORCID: 0009-0000-0683-9198
AD  - Department of Prophylaxis of Metabolic Diseases, Institute of Animal Reproduction 
      and Food Research, Polish Academy of Sciences in Olsztyn, Bialystok, Poland.
FAU - Straczkowski, Marek
AU  - Straczkowski M
AUID- ORCID: 0000-0001-5833-2305
AD  - Department of Prophylaxis of Metabolic Diseases, Institute of Animal Reproduction 
      and Food Research, Polish Academy of Sciences in Olsztyn, Bialystok, Poland.
LA  - eng
PT  - Journal Article
PL  - United Arab Emirates
TA  - Endocr Metab Immune Disord Drug Targets
JT  - Endocrine, metabolic & immune disorders drug targets
JID - 101269157
RN  - 0 (Insulin)
RN  - 0 (Receptors, Interleukin-1)
RN  - 0 (Interleukins)
RN  - 0 (IL-38 protein, human)
SB  - IM
MH  - Female
MH  - Humans
MH  - *Insulin Resistance
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism
MH  - Insulin
MH  - Inflammation
MH  - Receptors, Interleukin-1
MH  - Interleukins
OTO - NOTNLM
OT  - IL-38
OT  - glucose metabolism
OT  - inflammation
OT  - insulin resistance
OT  - insulin sensitivity
OT  - proinflammatory pathways.
EDAT- 2023/09/13 06:41
MHDA- 2024/02/22 06:43
CRDT- 2023/09/13 05:43
PHST- 2023/03/20 00:00 [received]
PHST- 2023/07/07 00:00 [revised]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2024/02/22 06:43 [medline]
PHST- 2023/09/13 06:41 [pubmed]
PHST- 2023/09/13 05:43 [entrez]
AID - EMIDDT-EPUB-134399 [pii]
AID - 10.2174/1871530323666230911114150 [doi]
PST - ppublish
SO  - Endocr Metab Immune Disord Drug Targets. 2024;24(6):611-616. doi: 
      10.2174/1871530323666230911114150.